Clinical resistance to topoisomerase-targeted drugs

Biochimica et Biophysica Acta - Gene Structure and Expression

Volumn 1400, Issue 1-3, 1998, Pages 275-288

  Dingemans, Anne Marie C ^a   Pinedo, Herbert M ^a   Giaccone, Giuseppe ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Chemotherapy; DNA topoisomerase; Drug resistance; Human tumor; Topoisomerase inhibitor

Indexed keywords

DNA TOPOISOMERASE;

CANCER CELL; CELL DEATH; CELL PROLIFERATION; DNA DAMAGE; DNA REPLICATION; DNA STRAND BREAKAGE; DRUG TARGETING; ENZYME ACTIVITY; ENZYME INHIBITION; NONHUMAN; PRIORITY JOURNAL; REVIEW; SOLID TUMOR;

ANTINEOPLASTIC AGENTS; CELL CYCLE; DNA TOPOISOMERASES, TYPE I; DNA TOPOISOMERASES, TYPE II; DRUG RESISTANCE; ENZYME INHIBITORS; HUMANS; LEUKEMIA; NEOPLASMS; TUMOR CELLS, CULTURED;

EID: 0032190565     PISSN: 01674781     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0167-4781(98)00141-9     Document Type: Review

References (90)

1. Bailar J.C., Gornik H.L. Cancer undefeated. New Engl. J. Med. 336:1997;1569-1574.
2. Wall M.E., Wani M.C., Cooke C.E., Palmer K.H., McPhail A.T., Slim G.A. The isolation and structure of camptothecin, a novel alkaloidal leukemia and tumor inhibitor from Camptotheca acuminata. J. Am. Chem. Soc. 88:1966;3888-3890.
3. Liu S.Y., Hwang B.D., Liu Z.C., Cheng Y.C. Interaction of several nucleoside triphosphate analogues and 10-hydroxycamptothecin with human DNA topoisomerases. Cancer Res. 49:1989;1366-1370.
4. D'Arpa P., Liu L.F. Topoisomerase-targeting antitumor drugs. Biochim. Biophys. Acta. 989:1989;163-177.
5. Capranico G., Kohn K.W., Pommier Y. Local sequence requirements for DNA cleavage by mammalian topoisomerase II in the presence of doxorubicin. Nucleic Acids Res. 18:1990;6611-6619.
6. Zwelling L.A., Hinds M., Chan D., Mayes J., Sie K.L., Parker E., Silberman L., Radcliffe A., Beran M., Blick M. Characterization of an amsacrine-resistant line of human leukemia cells. J. Biol. Chem. 264:1989;16411-16420.
7. Giaccone G., Gazdar A.F., Beck H., Zunino F., Capranico G. The multidrug sensitivity phenotype of human lung cancer cells associated with topoisomerase II expression. Cancer Res. 52:1992;1666-1674.
8. Fry A.M., Chresta C.M., Davies S.M., et al. Relationship between topoisomerase II level and chemosensitivity in human tumor cell lines. Cancer Res. 51:1991;6592-6595.
9. Kasahara K., Fujiwara Y., Sugimoto Y., Nishio K., Tamura T., Matsuda T., Saijo N. Determinants of response to the DNA topoisomerase II inhibitors doxorubicin and etoposide in human lung cancer cell lines. J. Natl. Cancer Inst. 84:1992;113-118.
10. Gudkov A.V., Zelnick C.R., Zakarov A.R., et al. Isolation of genetic suppressor elements, inducing resistance to topoisomerase II-interactive cytotoxic drugs, from human topoisomerase II cDNA. Proc. Natl. Acad. Sci. USA. 90:1993;3231-3235.
11. Markovits J., Junqua S., Goldwasser F., Venuat A.M., Luccioni C., Beaumatin J., Saucier J.M., Bernheim A., Jacquemin-Sablon A. Genistein resistance in human leukaemic CCRF-CEM cells: selection of a diploid cell line with reduced DNA topoisomerase II beta isoform. Biochem. Pharmacol. 50:1995;177-186.
12. Brown G.A., McPherson J.P., Gu L., et al. Relationship of DNA topoisomerase IIα and β expression to cytotoxicity of antineoplastic agents in human acute lymphoblastic leukemia cell lines. Cancer Res. 55:1995;78-82.
13. Beck W.T., Danks M.K., Wolverton J.S., Kim R., Chen M. Drug resistance associated with altered DNA topoisomerase II. Adv. Enzyme Regul. 33:1993;113-127.
14. Giaccone G. DNA topoisomerases and topoisomerase inhibitors. Pathol. Biol. 4:1994;346-352.
15. Sugimoto Y., Tsukahara S., Oh-hara T., Liu L.F., Tsuruo T. Elevated expression of DNA topoisomerase II in camptothecin-resistant human tumor cell lines. Cancer Res. 50:1990;7962-7965.
16. Tan K.B., Mattern M.R., Eng W.-K., McCabe F.L., Johnson R.K. Nonproductive rearrangement of DNA topoisomerase I and II genes: correlation with resistance to topoisomerase inhibitors. J. Natl. Cancer Inst. 81:1989;1732-1735.
17. Fujimori A., Hoki Y., Popescu N.C., Pommier Y. Silencing and selective methylation of the normal topoisomerase I gene in camptothecin-resistant CEM/C2 human leukemia cells. Oncol. Res. 8:1996;295-301.
18. Leteurtre F., Kohlhagen G., Fesen M.R., Tanizawa A., Kohn K.W., Pommier Y. Effects of DNA methylation on topo I and II cleavage activities. J. Biol. Chem. 269:1994;7893-7900.
19. Vassetzky Y.S., Alghisi G.-C., Gasser S.M. DNA topoisomerase II mutations and resistance to anti-tumor drugs. BioEssays. 17:1995;767-774.
20. Jansen W.J., Zwart B., Hulscher S.T., Giaccone G., Pinedo H.M., Boven E. CPT-11 in human colon-cancer cell lines and xenografts: characterization of cellular sensitivity determinants. Int. J. Cancer. 70:1997;335-340.
21. Shustik C., Dalton W., Gros P. P-glycoprotein-mediated multidrug resistance in tumor cells: biochemistry, clinical relevance and modulation. Mol. Asp. Med. 16:1995;1-78.
22. Izquierdo M.A., Shoemaker R.H., Flens M.J., Scheffer G.L., Wu L., Prather T.R., Scheper R.J. Overlapping phenotypes of multidrug resistance among panels of human cancer-cell lines. Int. J. Cancer. 65:1996;230-237.
23. Pommier Y., Leteurtre F., Fesen M.R., Fujimori A., Bertrand R., Solary E., Kohlhagen G., Kohn K.W. Cellular determinants of sensitivity and resistance to DNA topoisomerase inhibitors. Cancer Invest. 12:1994;530-542.
24. Herzog C.E., Zwelling L.A., McWatters A., Kleinerman E.S. Expression of topoisomerase II, Bcl-2, and p53 in three human brain tumor cell lines and their possible relationship to intrinsic resistance to etoposide. Clin. Cancer Res. 1:1995;1391-1397.
25. Lowe S.W., Bodis S., McClatchey A., Remington L., Ruley H.E., Fisher D.E., Housman D.E., Jacks T. p523 status and the efficacy of cancer therapy in vivo. Science. 266:1994;807-810.
26. Kim R., Beck W.T. Differences between drug-sensitive and -resistant human leukemic CEM cells in c-jun expression, AP-1 DNA binding activity, and formation of Jun/Fos family dimers, and their association with internucleosomal DNA ladders after treatment with VM-26. Cancer Res. 54:1994;4958-4966.
27. Efferth T., Mattern J., Volm M. Immunohistochemical detection of P glycoprotein, glutathione S transferase and DNA topoisomerase II in human tumors. Oncology. 49:1992;368-375.
28. Negri C., Chiesa R., Cerino A., Bestagno M., Sala C., Zini N., Maraldi N.M., Astaldi Ricotti G.C.B. Monoclonal antibodies to human DNA topoisomerase I and the two isoforms of DNA topoisomerase II: 170- and 180-kDa isozymes. Exp. Cell Res. 200:1992;452-459.
29. Kreipe H., Alm P., Olsson H., Hauberg M., Fischer L., Parwaresch R. Prognostic significance of a formalin-resistant nuclear proliferation antigen in mammary carcinomas as determined by the monoclonal antibody Ki-S1. Am. J. Pathol. 142:1993;651-657.
30. Kellner U., Heidebrecht H.-J., Rudolph P., Biersack H., Buck F., Dakowski T., Eacker H.-H., Domanowski M., Seidel A., Westergaard O., Parwaresch R. Detection of human topoisomerase IIα in cell lines and tissues: characterization of five novel monoclonal antibodies. J. Histochem. Cytochem. 45:1997;251-263.
31. Holden J.A., Rolfson D.H., Wittwer C.T. Human DNA topoisomerase II: evaluation of enzyme activity in normal and neoplastic tissues. Biochemistry. 29:1990;2127-2134.
32. Holden J.A., Rolfson D.H., Wittwer C.T. The distribution of immunoreactive topoisomerase protein in human tissues and neoplasms. Oncol. Res. 4:1992;157-166.
33. McLeod H.L., Douglas F., Oates M., Symonds R.P., Prakash D., van der Zee A.G., Kaye S.B., Brown R., Keith W.N. Topoisomerase I and II activity in human breast, cervix, lung and colon cancer. Int. J. Cancer. 59:1994;607-611.
34. Boege F., Andersen A., Jensen S., Zeidler R., Kreipe H. Proliferation-associated nuclear antigen Ki-S1 is identical with topoisomerase IIα Am. J. Pathol. 146:1995;1302-1308.
35. Hellemans P., van Dam P.A., Geykens M., van Oosterom A.T., Buytaert P.H., van Mark E. Immunohistochemical study of topoisomerase IIα expression in primary ductal carcinoma of the breast. J. Clin. Pathol. 48:1995;147-150.
36. Lynch B.J., Guinee D.G., Holden J.A. Human DNA topoisomerase II-alpha: a new marker of cell proliferation in invasive breast cancer. Hum. Pathol. 28:1997;1180-1188.
37. Gibbons D., Fogt F., Kaznica J., Holden J., Nikulasson S. Comparison of topoisomerase II alpha and MIB-1 expression in uterine cervical squamous lesions. Mod. Pathol. 10:1997;409-413.
38. Jarvinen T.A., Kononen J., Pelto-Huikko M., Isola J. Expression of topoisomerase IIalpha is associated with rapid cell proliferation, aneuploidy, and c-erbB2 overexpression in breast cancer. Am. J. Pathol. 148:1996;2073-2082.
39. Sandri M.I., Hochhauser D., Ayton P., Camplejohn R.C., Whitehouse R., Turley H., Gatter K., Kichson I.D., Harris A.L. Differential expression of the topoisomerase II alpha and beta genes in human breast cancers. Br. J. Cancer. 73:1996;1518-1524.
40. D'Andrea M.R., Farber P.A., Foglesong P.D. Immunohistochemical detection of DNA topoisomerases IIα and IIβ compared with detection of Ki-67, a marker of cellular proliferation, in human tumors. Appl. Immunohistochem. 2:1994;177-185.
41. Ito K., Susano H., Yabuki N., Matsunaga G., Sato S., Kikuchi A., Yajiama A., Nagura H. Immunohistochemical study of Ki-67 and DNA topoisomerase II in human endometrium. Mod. Pathol. 10:1997;289-294.
42. Yuwen H., Hsia C.C., Nakashima Y., Evangelista A., Tabor E. Binding of wild-type p53 to topoisomerase II and overexpression of topoisomerase II in human hepatocellular carcinoma. Biochem. Biophys. Res. Commun. 234:1997;194-197.
43. Turley H., Comley M., Houlbrook S., Nozaki N., Kikuchi A., Hickson I.D., Gatter K., Harris A.L. The distribution and expression of the two isoforms of DNA topoisomerase II in normal and neoplastic human tissues. Br. J. Cancer. 75:1997;1340-1346.
44. Bauman M.E., Holden J.A., Brown K.A., Harker W.G., Perkins S.L. Differential immunohistochemical staining for DNA topoisomerase IIα and β in human tissues and for DNA topoisomerase IIβ in non-Hodgkin's lymphomas. Mod. Pathol. 10:1997;168-175.
45. Yabuki N., Sasano H., Kato K., Ohara S., Toyota T., Nagura H., Miyaike M., Nozaki N., Kukuchi A. Immunohistochemical study of DNA topoisomerase II in human gastric disorders. Am. J. Pathol. 149:1996;997-1007.
46. Fogt F., Nikulasson S.T., Holden J.A., Alder S.A., Hallgrimsson J., Jessup M.J., O'Brien M.J., Lavin P.T., Goldman H. Topoisomerase IIα expression in normal, inflammatory, and neoplastic conditions of the gastric and colonic mucosa. Mod. Pathol. 10:1997;296-302.
47. Holden J.A., Perkins S.L., Snow G.W., Kjeldsberg C.R. Immunohistochemical staining for DNA topoisomerase II in non-Hodgkin's lymphomas. Am. J. Clin. Pathol. 104:1995;54-59.
48. Lohri A., Reuter J., Gudat F., Herrmann R. Topoisomerase IIα mRNA and tumour cell proliferation in non-Hodgkin's lymphoma. J. Clin. Pathol. 50:1997;22-26.
49. Giaccone G., Van Ark-Otte J., Scagliotti G., Capranico G., van der Valk P., Rubio G., Dalesio O., Lopez R., Zunino F., Walboomers J., Pinedo H.M. Differential expression of DNA topoisomerases in non-small cell lung cancer and normal lung. Biochim. Biophys. Acta. 1264:1995;337-346.
50. Guinee D.G., Holden J.A., Benfield J.R., Woodward M.L., Przygodzki R.M., Fishback N.F., Koss M.N., Travis W.D. Comparison of DNA topoisomerase IIα expression in small cell and nonsmall cell carcinoma of the lung; in search of a mechanism of chemotherapeutic response. Cancer. 78:1996;729-735.
51. Giovanella B.C., Stehlin J.S., Wall M.E., et al. DNA topoisomerase I targeted chemotherapy of human colon cancer xenografts. Science. 246:1989;1046-1048.
52. van der Zee A.G.J., Hollema H., de Jong S., Boonstra H., Gouw A., Willemse P.H.B., Zijlstra J.G., de Vries E.G.E. P-glycoprotein expression and DNA topoisomerase I and II activity in benign tumors of the ovary and in malignant tumors of the ovary, before and after platinum/cyclophosphamide chemotherapy. Cancer Res. 51:1991;5915-5920.
53. Husain I., Mohler J.L., Seigler H.F., Besterman J.M. Elevation of topoisomerase I mRNA, protein, and catalytic activity in human tumors: demonstration of tumor-type specificity and implications for cancer chemotherapy. Cancer Res. 54:1994;539-546.
54. Ohashi N., Fujiwara Y., Yamaoka N., Katoh O., Satow Y., Yamakido M. No alteration in DNA topoisomerase I gene related to CPT-11 resistance in human lung cancer. Jpn. J. Cancer Res. 87:1996;1280-1287.
55. Chen S.F., Rothenberg M.L., Clark G., Degen D., Wajima M., Barton D., Von Hoff D.D. Human tumor carboxylesterase activity correlates with CPT-11 cytotoxicity in vitro. Proc. Am. Assoc. Cancer Res. 35:1994;365.
56. Davies S.L., Popert R., Coptcoat M., Hickson I.D., Masters J.R. Response to epirubicine in patients with superficial bladder cancer and expression of the topoisomerase II alpha and beta genes. Int. J. Cancer. 65:1996;63-66.
57. Kim W.-J., Kakehi Y., Wu W.-J., Fukumoto M., Yoshida O. Expression of multidrug resistance genes (mdr1, MRP, GST-π and DNA topoisomerase II) in urothelial cancer. Br. J. Urol. 78:1996;361-368.
58. Volm M., Mattern J., Stammler G., Royer-Pokora B., Schneider S., Weirich A., Ludwig R. Expression of resistance-related proteins in nephroblastoma after chemotherapy. Int. J. Cancer. 63:1995;193-197.
59. Volm M., Mattern J. Expression of topoisomerase II, catalase, metallothionein and thymidylate-synthase in human squamous cell lung carcinomas and their correlation with doxorubicin resistance and with patients' smoking habits. Carcinogenesis. 13:1992;1947-1950.
60. Kim R., Hirabayashi N., Nishiyama M., Saeki S., Toge T., Okada K. Expression of MDR1, GST-π, and topoisomerase II as an indicator of clinical response to adriamycin. Anticancer Res. 11:1991;429-432.
61. Smith K., Houlbrook S., Greenall M., Carmichael J., Harris A.L. Topo IIα coamplification with erbB2 in human primary breast cancer and breast cancer cell lines: relationship to m-AMSA and mitoxantrone sensitivity. Oncogene. 8:1993;933-938.
62. van der Zee A.G.J., de Vries E.G.E., Hollema H., Kaye S.B., Brown R., Keith W.N. Molecular analysis of the topoisomerase IIα gene and its expression in human ovarian cancer. Ann. Oncol. 5:1994;75-81.
63. van der Zee A.G., de Jong S., Keith W.N., Hollema H., Boonstra H., de Vries E.G. Quantitative and qualitative aspects of topoisomerase I and II alpha and beta in untreated and platinum/cyclophosphamide treated malignant ovarian tumors. Cancer Res. 54:1994;749-755.
64. Kubo A., Yoshikawa A., Hirashima T., Masuda N., Takada M., Takahara J., Fukuoka M., Nakagawa K. Point mutations of the topoisomerase IIα gene in patients with small cell lung cancer treated with etoposide. Cancer Res. 56:1996;1232-1236.
65. Lee M.-S., Wang J.C., Beran M. Two independent amsacrine-resistant human myeloid leukemia cell lines share an identical point mutation in the 170 kDa form of human topoisomerase II. J. Mol. Biol. 223:1992;837-843.
66. Takatani H., Oka M., Fukuda M., Narasaki F., Nakano R., Ikeda K., Terashi K., Kinoshita A., Soda H., Kanda T., Schneider E., Kohno S. Gene mutation analysis and quantitation of DNA topoisomerase I in previously untreated non-small cell lung carcinomas. Jpn. J. Cancer Res. 88:1997;160-165.
67. Ishikawa H., Kawano M.M., Okada K., Tanaka H., Tanabe O., Sakai A., Asaoku H., Iwato K., Nobuyoshi M., Kuramoto A. Expressions of DNA topoisomerase I and II gene and the genes possibly related to drug resistance in human myeloma cells. Br. J. Haematol. 83:1993;68-74.
68. Pieters R., et al. Different types of non-P-glycoprotein mediated multiple drug resistance in children with relapsed acute lymphoblastic leukemia. Br. J. Cancer. 65:1992;691-697.
69. den Boer M.L., Pieters R., Kazemier K.M., Rottier M.M., Zwaan C.M., Kaspers G.J., Janka-Schaub G., Henze G., Creutzig U., Scheper R.J., Veerman A.J. Relationship between major vault protein/lung resistance protein, multidrug resistance-associated protein, P-glycoprotein expression, and drug resistance in childhood leukemia. Blood. 91:(6):1998;2092-2098.
70. Klumper E., Giaccone G., Pieters R., Broekema G., Van Ark-Otte J., Van Wering E.R., Kaspers G.J.L., Veerman A.J.P. Topoisomerase IIα gene expression in childhood acute lymphoblastic leukemia. Leukemia. 9:1995;1653-1660.
71. Kaufmann S.H., Karp J.E., Burke P.J., Gore S.D. Addition of etoposide to initial therapy of adult acute lymphoblastic leukemia: a combined clinical and laboratory study. Leuk. Lymphoma. 23:1996;71-83.
72. Cattan A.R., Levett D., Douglas E.A., Middleton P.G., Taylor P.R. Method for quantifying expression of functionally active topoisomerase II in patients with leukemia. J. Clin. Pathol. 49:1996;848-852.
73. Kaufmann S.H., Karp J.E., Jones R.J., Miller C.B., Schneider E., Zwelling L.A., Cowan K., Wendel K., Burke P.J. Topoisomerase II levels and drug sensitivity in adult acute myelogeneous leukemia. Blood. 83:1994;517-530.
74. Gieseler F., Glasmacher A., Kämpfe D., Wandt H., Nuessler V., Valsamas S., Kunze J., Wilms K. Topoisomerase II activities in AML blasts and their correlation with cellular sensitivity to anthracyclines and epipodophyllotoxins. Leukemia. 10:(Suppl. 3):1996;S46-S49.
75. Beck J., Niethammer D., Gekeler V. MDR1, MRP, topoisomerase IIα/β, and cyclin A gene expression in acute and chronic leukemias. Leukemia. 10:(Suppl. 3):1996;S39-S45.
76. Filipits M., Suchomel R.W., Zöchbauer S., Brunner R., Lechner K., Pirker R. MRP expression in acute myeloid leukemia has no impact on treatment outcome. Proc. Am. Assoc. Cancer Res. 38:1997;440.
77. Lohri A., van Hille B., Bacchi M., Fopp M., Joncourt F., Reuter J., Cerny T., Fey M.F., Herrmann R. Five putative drug resistance parameters (MDR1/P-glycoprotein, MDR-associated protein, glutathione-S-transferase, bcl-2 and topoisomerase IIα) in 57 newly diagnosed acute myeloid leukaemias. Eur. J. Haematol. 59:1997;206-215.
78. Nicklee T., Crump M., Hedley D.W. Effects of topoisomerase I inhibition on the expression of topoisomerase IIα measured with fluorescence image cytometry. Cytometry. 25:1996;205-210.
79. E. Montserrat, Rozman, Chronic lymphocytic leukemia: present status, Ann. Oncol. 6 (1995) 219-235.
80. Ribrag V., Massade L., Faussat A.M., Dreyfus F., Bayle C., Couyette A., Marie J.P. Drug resistance mechanisms in chronic lymphocytic leukemia. Leukemia. 10:1996;1944-1949.
81. Beck J., Niethammer D., Gekeler V. High mdr1- and mrp-, but low topoisomerase IIα-gene expression in B-cell chronic lymphocytic leukaemias. Cancer Lett. 86:1994;135-142.
82. Danks M.K., Warmoth M.R., Friche E., Granzen B., Bugg B.Y., Harker W.G., Zwelling L.A., Futscher B.W., Suttle D.P., Beck W.T. Single-strand conformational polymorphism analysis of the Mr 170,000 isozyme of DNA topoisomerase II in human tumor cells. Cancer Res. 53:1993;1373-1379.
83. Lion T. Control genes in reverse transcriptase-polymerase chain reaction assays. Leukemia. 10:1996;1527-1528.
84. Kidd V.J. Problematic controls for reverse transcriptase polymerase chain reactions (RT-PCR): an issue revisited. Leukemia. 10:1996;1841-1842.
85. Lion T. Appropriate controls for RT-PCR. Leukemia. 10:1996;1843.
86. Withoff S., Smit E.F., Meersma G.J., van den Berg A., Timmer-Bosscha H., Kok K., Postmus P.E., Mulder N.H., de Vries E.G.E., Buys C.H.C.M. Quantitation of DNA topoisomerase IIα messenger ribonucleic acid levels in a small cell lung cancer cell line and two drug resistant sublines using a polymerase chain reaction-aided transcript titration assay. Lab. Invest. 71:1994;61-66.
87. Grant C.E., Valdimarsson G., Hipfner D.R., Almquist K.C., Cole S.P.C., Deeley R.G. Overexpression of multidrug resistance-associated protein (MRP) increases resistance to natural product drugs. Cancer Res. 54:1994;357-361.
88. Ellis A.L., Nowak B., Plunkett W., Zwelling L.A. Quantification of topoisomerase-DNA complexes in leukemia cells from patients undergoing therapy with a topoisomerase-directed agent. Cancer Chemother. Pharmacol. 34:1994;249-256.
89. Olive P.L., Banath J.P., Durand R.E. Detection of etoposide resistance by measuring DNA damage in individual Chinese hamster cells. J. Natl. Cancer Inst. 82:1990;779-783.
90. Olive P.L., Durand R.E., Banath J.P., Evans H.H. Etoposide sensitivity and topoisomerase II activity in Chinese hamster V79 monolayers and small spheroids. Int. J. Radiat. Biol. 3:1991;453-466.